NCT02781493|UnknownPhase 4DMC
Loading search results
Sponsor study identifier
interventional
600
1 country
1
Study Start
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prucalopride based bowel cleansing regimen might be helpful to improve bowel cleansing quality before colonoscopy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 21, 2016
Actual (reported)May 24, 2016
Actual (reported)June 2016
Date type not reportedThis date has not been verified as actual or estimated.
March 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Difference of scores rating by Boston Bowel Preparation Scale between 2 groups.
This is an established rating scale to evaluate the quality of bowel prep. The ratings will be compared between 2 groups.
9 months
Polyp detection rate between 2 groups.
9 months
rate of adverse events between 2 groups.
9 months
2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
2 mg Placebo plus 2 L Polyethylene Glycol regimen
Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordDepartment of Gastroenterology, Qilu Hospital, Shandong University
Jinan, Shandong, 250012, China
Li Yanqing, MD, PhD
Qilu Hospital of Shandong University
First Submitted
May 21, 2016
First Posted
May 24, 2016
Study Start
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2017
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 27, 2016
Record last verified: 2016-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: